Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.

Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.

Item
http://www.wikidata.org/entity/Q47862153
T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and PerspectivesReceptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical developmentAssessment of sequence homology and immunologic cross-reactivity between tree shrew (Tupaia belangeri) and human IL-21.IL-21-driven neoplasms in SJL mice mimic some key features of human angioimmunoblastic T-cell lymphoma.Evaluation of assay interference and interpretation of CXCR4 receptor occupancy results in a preclinical study with MEDI3185, a fully human antibody to CXCR4Interleukin-21: a double-edged sword with therapeutic potential.IL-21 as a therapeutic target in inflammatory disorders.Achieving incompatible transplantation through desensitization: current perspectives and future directions.IL-21: a pleiotropic cytokine with potential applications in oncology.Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.Role of receptor occupancy assays by flow cytometry in drug development.Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.A weighted method for estimation of receptor occupancy for pharmacodynamic measurements in drug development.Multiplexing of receptor occupancy measurements for pharmacodynamic biomarker assessment of biopharmaceuticals.IL-21 Receptor Antagonist Inhibits Differentiation of B Cells toward Plasmablasts upon Alloantigen Stimulation.Receptor occupancy and blocking of STAT5 signaling by an anti-IL-7 receptor α antibody in cynomolgus monkeys.Disruption of Pathogenic Cellular Networks by IL-21 Blockade Leads to Disease Amelioration in Murine Lupus.
P2860

Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.

Item
http://www.wikidata.org/entity/Q47862153
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Anti-IL21 receptor monoclonal ...... phase I, first-in-human study.
@en
Anti-IL21 receptor monoclonal ...... phase I, first-in-human study.
@nl
type
label
Anti-IL21 receptor monoclonal ...... phase I, first-in-human study.
@en
Anti-IL21 receptor monoclonal ...... phase I, first-in-human study.
@nl
prefLabel
Anti-IL21 receptor monoclonal ...... phase I, first-in-human study.
@en
Anti-IL21 receptor monoclonal ...... phase I, first-in-human study.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P921
P356
P1433
P1476
Anti-IL21 receptor monoclonal ...... phase I, first-in-human study.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P921